The FDA Has Approved Pfizer-OPKO Health Partnered Ngenla (Somatrogon-ghla), Once-weekly, Human Growth Hormone Analog For Pediatric Patients With Growth Failure Due To Inadequate Secretion Of Endogenous Growth Hormone
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Ngenla, a once-weekly human growth hormone analog for pediatric patients with growth failure, developed in partnership between Pfizer and OPKO Health.
June 28, 2023 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OPKO Health's partnered product Ngenla has received FDA approval, potentially boosting its revenue and market share in the pediatric treatment sector.
FDA approval of a new drug typically leads to increased sales and revenue for the manufacturing company. Given OPKO Health's involvement in the development of Ngenla, this approval could significantly boost its market share in the pediatric treatment sector.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
POSITIVE IMPACT
Pfizer's partnered product Ngenla has received FDA approval, potentially boosting its revenue and market share in the pediatric treatment sector.
FDA approval of a new drug typically leads to increased sales and revenue for the manufacturing company. Given Pfizer's size and market presence, this approval could significantly boost its market share in the pediatric treatment sector.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75